<p>德克萨斯州休斯顿，2026 年 1 月 23 日（全球新闻稿）—— <strong>Nexalin Technology, Inc. (纳斯达克：NXL)</strong>（“公司” 或 “Nexalin”），非侵入性深层颅内频率刺激（DIFS™）的领导者，今天宣布收到纳斯达克证券市场有限责任公司（“NASDAQ”）于 2026 年 1 月 21 日发出的通知函（“通知函”），通知公司未能遵守纳斯达克上市规则 5550(a)(2) 中规定的最低出价要求，因此无法继续在纳斯达克上市。本新闻稿是根据纳斯达克上市规则 5810(b) 发布的，该规则要求在收到缺陷通知后及时披露。</p>
<p>纳斯达克上市规则 5550(a)(2) 要求上市证券的最低出价价格维持在每股 1.00 美元，上市规则 5810(c)(3)(A) 规定，如果缺陷持续 30 个连续的交易日，则视为未满足最低出价要求。根据公司股票在 30 个连续交易日的收盘出价，公司不再满足最低出价要求。</p>
<p>根据纳斯达克上市规则 5810(c)(3)(A)，公司被给予 180 个日历天的时间，直到 2026 年 7 月 20 日，以重新符合纳斯达克上市规则 5550(a)(2)。为了重新符合要求，公司股票的收盘出价必须在至少 10 个连续交易日内达到至少 1.00 美元。如果公司在 2026 年 7 月 20 日之前未能重新符合要求，公司可能有资格获得额外的时间以重新符合要求，或可能面临退市。</p>
<p>收到通知函对公司股票的上市没有立即影响，股票将继续在纳斯达克以 “NXL” 代码不间断交易。为了解决这个问题，公司打算持续监控其出价，并正在考虑各种措施以改善其财务状况和运营结果，公司预计这些措施将抵消对其交易价格的短期不利影响，并及时解决缺陷。目前公司不考虑进行反向股票拆分。</p>
<p><strong>关于 Nexalin Technology, Inc.</strong></p>
<p>Nexalin 设计和开发创新的神经刺激产品，以独特的方式帮助应对全球心理健康危机。Nexalin 的所有医疗设备被认为是非侵入性且对人体不可检测的。Nexalin 产品旨在利用生物电子医疗技术为那些受到心理健康问题困扰的人提供缓解。Nexalin 相信其神经刺激医疗设备能够穿透与心理健康障碍相关的中脑深层结构。Nexalin 相信其下一代设备中更深层穿透的波形将产生增强的患者反应，而不会产生任何不良副作用。Nexalin Gen-2 15 毫安神经刺激设备已在中国、巴西、阿曼和以色列获得批准。有关公司的更多信息，请访问：https://nexalin.com/。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含构成 “前瞻性声明” 的陈述。这些陈述涉及未来事件或 Nexalin 的未来财务表现。任何提及期望、预测或其他对未来事件或情况的描述，或不是历史事实的陈述（包括但不限于 Nexalin 或其管理层 “相信”、“期望”、“预期”、“计划”、“打算” 等类似表达的陈述）应被视为前瞻性声明，涉及的风险和不确定性可能导致实际事件或 Nexalin 的实际结果与前瞻性声明所指示的结果有重大差异。前瞻性声明受多种条件的制约，其中许多超出公司的控制，包括在公司截至 2024 年 12 月 31 日的 10-K 表格报告的风险因素部分以及其他向证券交易委员会提交的文件中列出的条件。这些文件的副本可在 SEC 的网站 www.sec.gov 上获取。这些前瞻性声明是在本声明日期作出的，可能会随着时间的推移而过时。除法律要求外，公司没有义务更新这些声明以反映修订或变化。</p>
<p><strong>联系方式：</strong></p>
<p>Crescendo Communications, LLC</p>
<p>电话：（212）671-1020</p>
<p>电子邮件：NXL@crescendo-ir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UWXdNU00zTXpjNE16Z3hJelV3TURFd09URXhNdz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UWXdNU00zTXpjNE16Z3hJelV3TURFd09URXhNdz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU5ZTE4NTEtZDJlOC00MDQ2LWJkZGQtYTRlNTFkZjQyOTRhLTUwMDEwOTExMy0yMDI2LTAxLTIzLWVu/tiny/Nexalin-Technology-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU5ZTE4NTEtZDJlOC00MDQ2LWJkZGQtYTRlNTFkZjQyOTRhLTUwMDEwOTExMy0yMDI2LTAxLTIzLWVu/tiny/Nexalin-Technology-Inc-.png"/></p>

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

<p>Nexalin Technology, Inc.（纳斯达克代码：NXL）收到了纳斯达克的通知，指出其未能满足每股最低出价要求 1.00 美元。该公司有 180 天的时间，直到 2026 年 7 月 20 日，通过维持所需的出价价格连续 10 个交易日来恢复合规。该通知不会影响 NXL 股票的当前交易。Nexalin 正在探索改善其财务状况的措施，但目前不考虑进行反向股票拆分</p>

<p>HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- <strong>Nexalin Technology, Inc. (Nasdaq: NXL)</strong> (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a notification letter (the &#34;Notification Letter&#34;) from the Nasdaq Stock Market LLC (the &#34;NASDAQ&#34;) dated January 21, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ. This press release is issued pursuant to NASDAQ Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.</p>
<div class="lb-trans"><p>德克萨斯州休斯顿，2026 年 1 月 23 日（全球新闻稿）—— <strong>Nexalin Technology, Inc. (纳斯达克：NXL)</strong>（“公司” 或 “Nexalin”），非侵入性深层颅内频率刺激（DIFS™）的领导者，今天宣布收到纳斯达克证券市场有限责任公司（“NASDAQ”）于 2026 年 1 月 21 日发出的通知函（“通知函”），通知公司未能遵守纳斯达克上市规则 5550(a)(2) 中规定的最低出价要求，因此无法继续在纳斯达克上市。本新闻稿是根据纳斯达克上市规则 5810(b) 发布的，该规则要求在收到缺陷通知后及时披露。</p>
</div><p>NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's shares for the 30 consecutive business days the Company no longer meets the minimum bid price requirement.</p>
<div class="lb-trans"><p>纳斯达克上市规则 5550(a)(2) 要求上市证券的最低出价价格维持在每股 1.00 美元，上市规则 5810(c)(3)(A) 规定，如果缺陷持续 30 个连续的交易日，则视为未满足最低出价要求。根据公司股票在 30 个连续交易日的收盘出价，公司不再满足最低出价要求。</p>
</div><p>In accordance with the NASDAQ Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until July 20, 2026, to regain compliance with NASDAQ Listing Rule 5550(a)(2). To regain compliance, the Company's shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive trading days. In the event that the Company does not regain compliance by July 20, 2026, the Company may be eligible for additional time to regain compliance or may face delisting.</p>
<div class="lb-trans"><p>根据纳斯达克上市规则 5810(c)(3)(A)，公司被给予 180 个日历天的时间，直到 2026 年 7 月 20 日，以重新符合纳斯达克上市规则 5550(a)(2)。为了重新符合要求，公司股票的收盘出价必须在至少 10 个连续交易日内达到至少 1.00 美元。如果公司在 2026 年 7 月 20 日之前未能重新符合要求，公司可能有资格获得额外的时间以重新符合要求，或可能面临退市。</p>
</div><p>The receipt of the Notification Letter has no immediate effect on the listing of the Company's shares, which will continue to trade uninterrupted on NASDAQ under the ticker &#34;NXL&#34;. To address this issue, the Company intends to continuously monitor its bid price and is in the process of considering various measures to improve its financial position and results of operations, which the Company expects to counter the short-term adverse effects on its trading price and cure the deficiency in due time. The Company is not considering a reverse stock split at this time.</p>
<div class="lb-trans"><p>收到通知函对公司股票的上市没有立即影响，股票将继续在纳斯达克以 “NXL” 代码不间断交易。为了解决这个问题，公司打算持续监控其出价，并正在考虑各种措施以改善其财务状况和运营结果，公司预计这些措施将抵消对其交易价格的短期不利影响，并及时解决缺陷。目前公司不考虑进行反向股票拆分。</p>
</div><p><strong>About Nexalin Technology, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Nexalin Technology, Inc.</strong></p>
</div><p>Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's medical devices are believed to be non-invasive and undetectable to the human body. The Nexalin products are developed to provide relief to those afflicted with mental health issues using bioelectronic medical technology. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.</p>
<div class="lb-trans"><p>Nexalin 设计和开发创新的神经刺激产品，以独特的方式帮助应对全球心理健康危机。Nexalin 的所有医疗设备被认为是非侵入性且对人体不可检测的。Nexalin 产品旨在利用生物电子医疗技术为那些受到心理健康问题困扰的人提供缓解。Nexalin 相信其神经刺激医疗设备能够穿透与心理健康障碍相关的中脑深层结构。Nexalin 相信其下一代设备中更深层穿透的波形将产生增强的患者反应，而不会产生任何不良副作用。Nexalin Gen-2 15 毫安神经刺激设备已在中国、巴西、阿曼和以色列获得批准。有关公司的更多信息，请访问：https://nexalin.com/。</p>
</div><p><strong>FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains statements that constitute &#34;forward-looking statements,&#34; These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含构成 “前瞻性声明” 的陈述。这些陈述涉及未来事件或 Nexalin 的未来财务表现。任何提及期望、预测或其他对未来事件或情况的描述，或不是历史事实的陈述（包括但不限于 Nexalin 或其管理层 “相信”、“期望”、“预期”、“计划”、“打算” 等类似表达的陈述）应被视为前瞻性声明，涉及的风险和不确定性可能导致实际事件或 Nexalin 的实际结果与前瞻性声明所指示的结果有重大差异。前瞻性声明受多种条件的制约，其中许多超出公司的控制，包括在公司截至 2024 年 12 月 31 日的 10-K 表格报告的风险因素部分以及其他向证券交易委员会提交的文件中列出的条件。这些文件的副本可在 SEC 的网站 www.sec.gov 上获取。这些前瞻性声明是在本声明日期作出的，可能会随着时间的推移而过时。除法律要求外，公司没有义务更新这些声明以反映修订或变化。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Crescendo Communications, LLC</p>
<div class="lb-trans"><p>Crescendo Communications, LLC</p>
</div><p>Tel: (212) 671-1020</p>
<div class="lb-trans"><p>电话：（212）671-1020</p>
</div><p>Email: NXL@crescendo-ir.com</p>
<div class="lb-trans"><p>电子邮件：NXL@crescendo-ir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UWXdNU00zTXpjNE16Z3hJelV3TURFd09URXhNdz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYzMTYwMSM3Mzc4MzgxIzUwMDEwOTExMw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU5ZTE4NTEtZDJlOC00MDQ2LWJkZGQtYTRlNTFkZjQyOTRhLTUwMDEwOTExMy0yMDI2LTAxLTIzLWVu/tiny/Nexalin-Technology-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ODU5ZTE4NTEtZDJlOC00MDQ2LWJkZGQtYTRlNTFkZjQyOTRhLTUwMDEwOTExMy0yMDI2LTAxLTIzLWVu/tiny/Nexalin-Technology-Inc-.png"/></p>

Nexalin Technology Receives Nasdaq Listing Status Notification | NXL Stock News

StockTitan

Nexalin Tech

Nexalin Technology 收到纳斯达克上市状态通知 | NXL 股票新闻